Concenter Biopharma of Jerusalem is developing a drug to treat and even prevent type 2 diabetes by restoring the body’s insulin sensitivity
A new drug being developed in Israel could be the answer to treating the main cause of Type 2 Diabetes, insulin resistance. According to Concenter BioPharma co-founder and CSO Prof. Mottie (Mordechai) Chevion, “the unique property” of the drug, called Zygosid-50 “is that it cancels out insulin resistance.
Of the 463 million people in the world with diabetes, up to 95 per cent have type 2 (T2D). In T2D, peripheral tissues – mostly muscles — are resistant to insulin, a hormone made by the pancreas to stabilize blood-sugar levels and enable the body to use and store sugar. Medications available today treat the symptoms and complications of T2D but do not solve the core problem of insulin resistance.
Diabetes is a global epidemic and is expected to grow. The estimated cost of treating diabetes per year is over $850 billion. More than 150 companies are developing diagnostics or applications for diabetes, but there are no drugs to treat the actual problem of insulin resistance without side effects. This is what we are doing. -- Dror Chevion
Zygosid-50, a drug under development in Israel, could be the first to restore near-normal cellular sensitivity to insulin, without side effects. Concenter BioPharma in Jerusalem is raising funds for clinical trials approved by the FDA based on evidence from earlier testing in animal models for T2D.
In December, Concenter Biopharma cofounder and CSO Prof. Mottie (Mordechai) Chevion won first place at the 17th Annual World Congress on Insulin Resistance, Diabetes and Cardiovascular Diseases.
For more information about Zygosid-50 or Concenter Biopharma visit the company's website.